News Search Results
Jul 07, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
over four years with 25% of the grant vesting each year.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jul 07, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
Jul 07, 2026, 08:00 ET Kalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NORTHBROOK, Ill., July 7, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
Jul 07, 2026, 08:00 ET Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson's Disease
SAN DIEGO, July 7, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase
More news about: Kenai Therapeutics/BIOCOM
Jul 07, 2026, 07:00 ET Mikart Appoints Darrin Schellin as Chief Executive Officer
continuity for clients, employees, and partners.Schellin brings more than 20 years of executive leadership experience across the pharmaceutical, biotechnology, and CDMO sectors. He has led organizations through growth, transformation, operational restructuring, commercial expansion, and long-term value
More news about: Mikart, LLC
Jul 06, 2026, 17:58 ET Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions
Motif's established global commercial organization and technical support capabilities, enabling broader access across academic, pharmaceutical, biotechnology, and clinical research organizations. The agreement is effective immediately, with Arima's Hi-C products and services for research
More news about: Active Motif
Jul 06, 2026, 17:44 ET Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions
Motif's established global commercial organization and technical support capabilities, enabling broader access across academic, pharmaceutical, biotechnology, and clinical research organizations. The agreement is effective immediately, with Arima's Hi-C products and services for research
More news about: Active Motif
Jul 06, 2026, 13:27 ET Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
guidance to a range of $76 million to $80 million, citing, in part, budget reductions, project cancellations, and delays affecting pharmaceutical and biotechnology customers. Following the announcement, Simulations Plus shares declined more than 24%.Additional concerns arose in July 2025 after Simulations
More news about: Johnson Fistel, PLLP
Jul 06, 2026, 13:14 ET Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
integration solutions. The acquisition expands Surplus Solutions' technical service capabilities and supports the Company's continued growth in the biotechnology, pharmaceutical, and life sciences sectors. Terms of the transaction were not disclosed.
More news about: DCM BioServices
Jul 06, 2026, 11:40 ET AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD
Issued on behalf of NOMAD Power Solutions, Inc. (Nasdaq: NMAD), formerly LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking
More news about: American News Group
Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
the goal is to widen the therapeutic window through engineering rather than to add more raw potency.Zymeworks (NASDAQ: ZYME) is a biotechnology company with multispecific antibody-engineering platforms used to design and develop novel biologics. Zymeworks offers a view of the platform-and-partnership
More news about: American News Group
Jul 06, 2026, 11:00 ET Auburn University to introduce biomedical engineering graduate and certificate programs
and two graduate certificates, all drawing on the university's established expertise in advanced biomedical technologies and systems."The biotechnology and biomanufacturing sectors within the state of Alabama are growing quickly, and they need engineers who are prepared to contribute on day one,"
More news about: Auburn University-College of Engineering
Jul 06, 2026, 10:15 ET Microscopy Software Market worth $3.09 billion by 2031 | MarketsandMarkets™
especially in the US and Canada. The region also benefits from a strong concentration of leading players, advanced research infrastructure, heavy biotechnology investment, and early adoption of AI-driven imaging platforms. In addition, strong demand from clinical diagnostics, personalized medicine, and
More news about: MarketsandMarkets
Jul 06, 2026, 09:30 ET Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important
More news about: Curis, Inc.
Jul 06, 2026, 08:45 ET NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader
More news about: NeuroSense
Jul 06, 2026, 08:30 ET Dx&Vx (DXVX) Partners with Over 40 Global Companies at BIO USA, "Focused Discussions on Overseas Out-Licensing Deals"
that the company conducted partnering meetings with over 40 global pharmaceutical and biotechnology companies at BIO USA, which took place in San Diego from June 22-25.BIO USA is the world's largest biotechnology business event, drawing more than 20,000 participants from pharmaceutical companies
More news about: Dx&Vx
Jul 06, 2026, 08:30 ET Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing
More news about: Anixa Biosciences, Inc.
Jul 06, 2026, 08:00 ET Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
transition between phases, ensuring the final vaccine meets all safety, purity, and regulatory standards.About Matica Biotechnology, Inc.Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at its purpose-built
More news about: Matica Biotechnology, Inc.
Jul 06, 2026, 08:00 ET Lupin Named Among World's Most Sustainable Companies by TIME and Statista
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Jul 06, 2026, 06:40 ET Animal Feed Probiotic Market to Reach 8,384.4 Million by 2036 as Livestock Health Optimization and Antibiotic-Free Feed Strategies Accelerate Global Demand
dosing equipment and precision spraying systems further improve formulation consistency and operational efficiency.Research institutions and biotechnology companies are also developing customized probiotic blends designed for poultry, swine, ruminants, aquaculture, and companion animals. By utilizing
More news about: Future Market Insights
Jul 05, 2026, 21:10 ET Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
presentation at EASD 2026]About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jul 05, 2026, 20:27 ET Startup Island TAIWAN Bridges Tech Hubs, Launching East Coast Biotech Initiative in Boston
long-term, high-value collaborations between Taiwan and Boston's premier biotech ecosystem.In partnership with the Development Center for Biotechnology (DCB), the NDC recently led a delegation of Taiwanese biomedical startups to Boston for a four-day ecosystem engagement program from June 29 to
More news about: Development Center for Biotechnology
Jul 04, 2026, 05:01 ET Chandigarh University Uttar Pradesh Introduces 17 New-Age Academic Programs in Emerging Domains to Nurture a Futuristic Workforce
growing opportunities in research and health sciences, Chandigarh University Uttar Pradesh has introduced B.Sc. Microbiology and M.Sc. Biotechnology. The Biotechnology programme is positioned as a research-focused postgraduate course with emphasis on genomics, molecular biology, bioprocess technology
More news about: Chandigarh University
Jul 03, 2026, 10:30 ET Biomarkers Market worth $112.10 billion by 2031 | MarketsandMarkets™
others.Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jul 03, 2026, 04:03 ET Startup Island TAIWAN-Led Delegation Secures More Than 100 Business Meetings at BIO 2026, Expanding Global Opportunities for Taiwanese Biotech Startups
by the National Development Council's (NDC) national startup brand, Startup Island TAIWAN, the delegation was led by the Development Center for Biotechnology (DCB) through the Taiwan–Berkeley Health Innovation Accelerator. It brought together six Taiwanese biomedical startups—AB DigiHealth Inc. in AI-powered
More news about: DCB